reason report
multipl shot goal catalyst rich initi mp
bottom line initi coverag aslan
pharmaceut asln market perform rate
price target asln oncology-focus biopharmaceut compani
base singapor develop therapeut global market lead
program varlitinib revers small molecul pan-human epiderm
growth factor receptor pan-her inhibitor target
varlitinib origin licens arri
complet five phase studi rang solid tumor asln
develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer view asln well posit
execut clinic strategi asia focus develop
platform multipl shot goal catalyst rich
howev varlitinib clinic data gener date asln
arri demonstr activ want see
clinic mechanist valid varlitinib given biliari tract
cancer histor difficult space drug develop
mechanist advantag varlitinib pan-her inhibitor
remain unclear given implic target remain poorli
understood overal posit asln asia focus
develop strategi experi manag team
would want see clinic mechanist valid varlitinib
multipl shot goal catalyst rich aslan
conduct global pivot phase ii treetopp clinic trial varlitinib
combin capecitabin biliari tract cancer
top-lin data trial expect data readout
expect multipl studi includ pivot clinic
trial varilitinib combin capecitabin china line
biliari tract cancer top-lin data expect late phase
i/ii studi varlitinib combin gemcitabin plu cisplatin
line biliari tract cancer interim data expect late
global phase ii/iii clinic trial varlitinib combin folfox
co-express line gastric cancer top-lin data
expect phase ii clinic trial evalu
dhodh inhibitor acut myeloid leukemia aml interim data
expect
asia-focus develop platform sever advantag
asln manag team extens experi develop
commerci drug asia includ ceo carl firth
previous new product director china busi develop
director asia pacif azn asln also local presenc asia
team singapor taiwan china enabl execut
clinic trial addit asln develop lead program varlitinib
indic high preval asia includ biliari tract cancer
gastric cancer facilit time clinic progress
multipl dr tgr
net debt total capit
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
activ demonstr previou varlitinib studi although
question remain data previous gener asln arri
demonstr activ varlitinib question remain
would want see clinic mechanist valid
program addit biliari tract cancer remain signific
unmet medic need biliari tract cancer histor
difficult space drug develop although also mean bar
success low also mechanist implic advantag
pan-her inhibitor includ target remain poorli
understood although breast cancer cell line data
indic could play role acquir resist
multipl sourc upsid estim current
assign valu earlier stage program includ
 receptor inhibitor ron/met inhibitor
current phase ii studi aml interim data
expect current pre-clin develop
sever atop dermat asthma ind submiss expect
small molecul inhibitor hepatocyt growth
factor receptor cmet recepteur dorigin nantai ron
immun checkpoint inhibitor current partner bristol-
asln oncology-focus biopharmaceut compani base singapor develop therapeut global market
lead program varlitinib revers small molecul pan-human epiderm growth factor receptor pan-her inhibitor target
varlitinib origin licens arri complet five phase studi rang solid
tumor asln develop varlitinib indic high preval asia includ biliari tract cancer gastric cancer view
asln well posit execut clinic strategi asia-focus develop platform multipl shot goal
catalyst rich howev varlitinib clinic data gener date asln arri demonstr
activ want see clinic mechanist valid varlitinib given biliari tract cancer histor difficult
space drug develop mechanist advantag varlitinib pan-her inhibitor remain unclear given implic
target remain poorli understood overal posit asln asia-focus develop strategi
experi manag team would want see clinic mechanist valid varlitinib catalyst rich
 price target asln base blend dcf analysi revenu multipl analysi assign
valu probability-weight us china sale varlitinib biliari tract cancer probabl success gastric cancer
probabl success assum royalti row sale futur partnership varlitinib opportun
breast cancer remain upsid estim earlier stage program partner
repres also upsid valuat use discount rate termin growth rate
 asln pipelin program face clinic regulatori develop risk well commerci intellectu properti risk asln
also face execut risk financi risk asln may addit financ need turn cash flow posit
aslan clinic stage compani develop target drug molecul diseas rel higher preval asian
countri orphan diseas countri aslan incorpor singapor aslan pipelin product includ
varlitinib pan-her inhibitor dhodh inhibitor receptor inhibitor aslan one partner
program ron/met inhibitor latter global right program lead indic varlitinib includ
biliari tract cancer gastric cancer higher preval asian countri vs western countri orphan diseas
us europ
varlitinib lead molecul oral revers small molecul pan-her inhibitor current clinic develop biliari
tract cancer gastric cancer drug receiv orphan drug design fda gastric cancer cholangiocarcinoma varlitinib
shown low nanomolar nm potenc famili preclin model report select inhibit famili could
potenti translat fewer off-target effect aslan licens varlitinib arri success complet five phase clinic
trial rang solid tumor includ breast cancer januari aslan enter new licens agreement arri
aslan obtain exclus world-wide licens develop manufactur commerci varlitinib human anim therapeut
diagnost prophylact use
sever clinic trial on-going catalyst rich aslan conduct global pivot phase ii treetopp clinic trial varlitinib
combin capecitabin line biliari tract cancer top-lin data trial expect compani anoth
pivot clinic trial varlitinib combin capecitabin china line biliari tract cancer top-lin data expect
aslan also on-going phase i/ii studi varlitinib combin gemcitabin plu cisplatin line biliari tract cancer interim
data expect compani also conduct global phase ii/iii clinic trial varlitinib combin folfox
co-express line gastric cancer top-lin data expect aslan conduct phase ii clinic trial develop
acut myeloid leukemia aml expect report interim data
posit phase ii data line biliari tract cancer could lead expedit approv varlitinib us china base fda
guidanc aslan intend seek acceler approv varlitinib later line biliari tract cancer base posit respons rate
current standard care china compani anoth pivot clinic trial varlitinib combin capecitabin line biliari tract
cancer top-lin data expect accord manag cfda china food drug administr agre
compani seek approv china trial meet primari endpoint
pipelin program still earli fulli human monoclon antibodi target receptor subunit
current pre-clin develop sever atop dermat asthma aslan plan submit ind third quarter
small molecul inhibitor hepatocyt growth factor receptor cmet recepteur dorigin nantai ron immun
checkpoint inhibitor current partner bm
programpartnertargetindicationstatuseventtimingclinicaltri govvarlitinib pharm korea pan-herbiliari tract cancer treetopp pivot ph ii trial line global w/ capecitabin top-lin ph ii trial line china w/ capecitabin top-lin i/ii line w/ gemcitabin cisplatin interim ii line singl agent complet cancerph ii line w/ folfox top-lin carcinoma ph i/ii line istrecruitinginiti may cancerph ii amplifi post-herceptin line w/ capecitabin complet tumor sponsor arri ph complet tumor sponsor arri ph w/ capecitabin complet tumor sponsor arri ph w/ gemcitabin complet tumor sponsor arri ph w/ docetaxel complet ii interim dermatitispreclinicalind product global right ron/metsolid tumorsph icomplet compani file leerink partner estimatesaslan pipelin upcom event aslan ltd
indic like biliari gastric
high preval asia multipl shot
goal catalyst rich
view bull investor case
competit target space
signific pan-her differenti
unclear biliari gastric
difficult area drug develop
view bear investor case
leverag manag team
extens experi asia
pursu indic high preval
asia facilit time clinic
multipl shot goal catalyst rich
multipl sourc upsid
varlitinib compet crowd
target space advantag
unmet medic need difficult
area drug develop
drug develop includ failur
multipl target agent past
lead molecul varlitinib oral revers small molecul pan-her inhibitor current clinic develop
biliari tract cancer gastric cancer varlitinib shown low nanomolar nm potenc famili preclin model
varlitinib report select inhibit famili could potenti translat fewer off-target effect drug
receiv orphan drug design fda gastric cancer cholangiocarcinoma
 aslan conduct global pivot phase ii treetopp clinic trial varlitinib combin capecitabin line
biliari tract cancer top-lin data trial expect compani anoth pivot clinic trial varlitinib
combin capecitabin china line biliari tract cancer top-lin data expect aslan also
on-going phase i/ii studi varlitinib combin gemcitabin plu cisplatin line biliari tract cancer interim data
expect
base fda guidanc compani intend seek acceler approv varlitinib base posit respons rate
current standard care
 compani also conduct global phase ii/iii clinic trial varlitinib combin folfox co-
express line gastric cancer top-lin data expect
preclin studi varlitinib shown encourag vitro potenc nm rang pathway inhibit
gastric cancer model express egfr epiderm growth factor receptor varlitinib shown anti-tumor activ
support rational on-going clinic studi gastric cancer patient co-express varlitinib also
shown sustain inhibit egfr preclin model
aslan licens varlitinib arri success complet five phase clinic trial rang solid
tumor includ breast cancer januari aslan enter new licens agreement arri aslan
obtain exclus world-wide licens develop manufactur commerci varlitinib human anim therapeut
diagnost prophylact use
varlitinib preclin data erbb inhibit egfr
varlitinib gastric carcinoma model egfr express
gastric carcinoma
high level egfr
also reli
prolifer
surviv
varlitinib gastric carcinoma model egfr
express vs trastuzumab
combin trastuzumab
varlitinib gastric carcinoma model egfr
express vs capecitabin
combin capecitabin
varlitinib preclin result show sustain inhibit egfr
phase studi evalu varlitinib tablet single-ag safeti preliminari
efficaci patient advanc solid tumor includ non-smal cell
lung cancer nsclc colorect breast cervic cancer
mg bid tablet dose level determin non-toler dose
mg bid dose level expand confirm dose level
area curv auc valu part pharmacokinet analysi
mg bid tablet dose similar mg bid capsul
varlitinib activ metastat
patient prior herceptin-bas regimen
patient prior lapatinib tx
varlitinib activ solid tumor
random phase ii open label studi compar efficaci safeti varlitinib plu capecitabin vc vs lapatinib
plu capecitabin lc metastat breast cancer patient fail prior trastuzumab therapi primari
object studi assess percentag chang tumor size week object respons rate orr via recist safeti
drug exposur also assess secondari endpoint
 percentag tumor size reduct numer higher varlitinib plu capecitabin vs one-sid
 orr varlitinib plu capecitabin arm pr vs pr lapatinib plu capecitabin
sensit analysi perform patient remain
studi beyond first day sensit
analys exclud patient tumor size analysi
patient analysi orr
patient withdrew vc arm state reason
comparison activ safeti profil varlitinib target tki
breast cancer metastat varlitinib plu xelodalapatinib plu xelodaneratinib plu xelodalapatinib plu plu xelodastudyph iiph patient populationm breast cancerm breast cancer fish na herceptin adj met mg bid mg qd mg qd mg qd mg/kg mg qd monthssafeti gr leerink partner research central confirm breast cancer line ph ii randomizedph emiliam breast cancer line aslan pharmaceut ltd
treetopp random double-blind placebo-control studi evalu varlitinib line biliari tract cancer
trial random patient prior chemotherapi either varlitinib plu capecitabin arm placebo
 overal respons rate orr progression-fre surviv co-primari endpoint endpoint assess
independ central review icr accord recist secondari endpoint includ overal surviv os durat respons
dor diseas control rate dcr tumor size percentag chang week defin recist
 endpoint analysi perform use hochberg procedur data consid posit either co-
primari endpoint achiev signific level one-sid alpha co-primari endpoint achiev signific
level one-sid top-lin data expect
 accord manag compani file acceler approv line biliari tract cancer data
posit compani intend run second confirmatori trial demonstr improv overal surviv case
varlitinib phase ii pivot treetopp studi biliari tract cancer line
china aslan on-going single-arm pivot clinic trial varlitinib plu capecitabin line biliari tract cancer
trial expect enrol patient whose diseas progress prior chemotherapi
 object respons rate orr primari endpoint key secondari endpoint progression-fre surviv
 accord manag cfda china food drug administr agre compani seek approv
china trial meet primari endpoint
phase ib/ii studi line biliari tract cancer on-going compani initi phase ib/ii studi evalu safeti
toler efficaci varlitinib plu gemcitabin cisplatin line biliari tract cancer
 phase ib portion plan determin maximum toler dose varlitinib combin chemotherapi
line biliari tract cancer
 upon reach trial progress phase ii portion plan two-arm double-blind placebo-
control trial compar varlitinib plu gemcitabine/cisplatin vs placebo plu gemcitabine/cisplatin total patient
 primari endpoint trial assess icr accord recist criteria
 secondari endpoint includ orr os
varlitinib plu chemotherapi combin show respons rate biliari tract cancer patient on-going phase
ib studi varlitinib combin doublet chemotherapi platinum plu fluoropyrimidin respons rate pr
report biliari tract cancer patient two prior treatment patient achiev stabl diseas
 durat respons dor week report
august compani initi global random double-blind placebo-control phase ii/iii studi line
gastric cancer co-express evalu varlitinib plu folfox vs placebo plu folfox phase ii portion
expect enrol patient co-express elig herceptin treatment
 compani expect report top-lin data primari endpoint percentag chang tumor size target lesion
week compar baselin assess independ central review icr accord respons evalu criteria
solid tumor version recist secondari endpoint includ object respons rate orr progression-fre surviv
overal surviv os
 accord manag studi expect progress phase phase ii result meet primari endpoint
percentag reduct tumor size week statist signific one-sid phase trial expect
enrol addit patient overal surviv os primari endpoint
varlitinib phase ii studi gastric cancer line co-express
studi design evalu biolog activ varlitinib tumor biopsi sampl relapsed/refractori
gastric cancer patient either co-express amplif patient dose varlitinib mg bid
 patient enrol includ patient upregul patient amplif
 inhibit phospho-mapk down-regul indic reduc tumor prolifer inhibit
phospho-akt upregul tunel indic tumor cell death varlitinib report downregul prolifer
upregul tumor apoptosi evalu patient
 find support preclin data led initi on-going phase ii/iii studi co-express
varlitinib show posit biomark data
receptor
compos extracellular ligand-bind domain
transmembran domain tyrosin kinas domain upon
ligand bind receptor activ auto- cross-
phosphoryl among famili member
preferenti dimer partner dimer subsequ
phosphoryl lead activ downstream target
includ raf/mek/mapk pathway
activ pathway enhanc surviv prolifer
 human egf receptor famili consist four member
belong erbb lineag protein
famili receptor ubiquit express
epitheli mesenchym neuron cell cellular
 seven growth factor report bind
none bind two bind
seven ligand bind
 although fail bind growth overexpress
lead format function homodim
heterodim combin
also report exhibit robust signal activ
 receptor kinas impair induc
homodim format would fail stimul protein kinas
activ downstream signal howev kinase-impair
possess autophosphoryl activ
organ erbb receptor
famili receptor interact drug class downstream signal
breast cancer metastat prior chemo herceptin
breast cancer metastat prior chemo herceptin
vitro activ tki egfr
diarrhea dose-limit toxic dlt
sever small molecul egfr tki
commonli observ side effect
egfr inhibitor acneiform erupt
also call acne-lik rash follicul
report occur patient
agenttargetmoleculetickercurr phaseind namevarlitinibegfr moleculeaslnii/iiigastr egfrsmal moleculepbyiiigastr cancerpoziotinibegfr moleculesppiiigastr antibodymgnxi/iiesophag antibodymgnxi/iigastr antibodyf-star alpha ltd igastr antibodyzymeigastr antibodydskyfdevelop outsid gastric outsid gastric cancerpyrotinibegfr outsid gastric egfrsmal moleculepbyiiisolid antibodymrusi/iisolid antibodysymphogen a/si/iisolid antibodyadc saisolid antibodydskyfisolid tumorsgbr antibodygnp inisolid tumorsgilotrifpan-hersmal moleculeboehring ingelheim gmbhisolid antibodyaznisolid antibodypfeisolid antibodyglycotop groupisolid biotechisolid antibodymrsnisolid outsid solid tumorsvarlitinibegfr moleculeaslnii/iiibiliari tract outsid brain cancer malign glioma aa glioblastoma egfrsmal moleculenvsiibrain cancer malign glioma aa glioblastoma gbm tesevatinibegfr vegfr moleculekdmniibrain cancer secondari egfrsmal moleculepbyiiicerv antibodydskyfiicolorect cancer gilotrifpan- hersmal moleculeboehring ingelheim gmbhiiihead neck cancerpoziotinibegfr moleculesppiiihead neck cancervarlitinibegfr moleculeaslnihepatocellular liver cancer includ secondari egfrsmal moleculepbyiiinon-smal cell lung cancer nsclc pirotinibegfr cell lung cancer nsclc poziotinibegfr moleculesppiiinon-smal cell lung cancer moleculetkpyyi/iinon-smal cell lung cancer nsclc tesevatinibegfr vegfr moleculekdmniinon-smal cell lung cancer biopharma inc iovarian antibodyrhhbyiiiovarian moleculeoncxiovarian antibodyzymeiovarian cancertesevatinibegfr vegfr moleculekdmni/iipolycyst kidney cancer aslan ltd
earli data suggest mediat acquir resist inhibitor breast cancer cell although much effort
focus elucid mechan acquir resist therapi involv remain
elus controversi earli data suggest efficaci pan-her inhibitor least part mediat inhibit
moreov upregul protein level breast cancer cell line select acquir lapatinib
resist vitro mmtv-neu mice follow prolong lapatinib treatment knockdown also trigger apoptosi
lapatinib resist cell also trastuzumab-resist cell earli data suggest dispens nave
breast cancer cell may play key role surviv cell develop resist inhibitor like lapatinib
protein level modestli up-regul lapatinib-resist cell
biliari tract cancer btc repres second common type hepatobiliari cancer world-wide typic
classifi intrahepat cholangiocarcinoma icca perihilar/hilar cholangiocarcinoma pcca distal cholangiocarcinoma dcca
gallbladd cancer gbc intrahepat cca aris biliari epithelium small duct peripheri liver
extrahepat cca aris main duct hilum extrahepat perihilar cca common type
cca intrahepat perihilar distal extrahepat ghouri et al
 western world incid cholangiocarcinoma per annual incid intrahepat
 howev china thailand rel higher incid report time rate observ unit
studi ross et al demonstr biliari tract cancer share genom aberr cell cycl regul
specif chromatin remodel intrahepat cholangiocarcinoma featur fibroblast growth factor receptor
fgfr fusion substitut braf substitut amplif low kra mutat frequenc
amplif pathway aberr common extrahepat cholangiocarcinoma
complet resect chemotherapi remain current standard care biliari tract cancer complet resect remain
gold standard treatment offer best chanc cure patient biliari tract cancer even complet
resect overal surviv rate rang intrahepat cholangiocarcinoma perihilar lesion
distal cholangiocarcinoma nation cancer research institut uk advanc biliari tract cancer
random phase studi establish cisplatin gemcitabin refer chemotherapi regimen advanc biliari
tract cancer median overal surviv month
 recent meta-analysi show signific benefit overal surviv patient receiv adjuv therapi cur resect
limit success seen target therapi variou target agent use clinic set clinic data
gener date look underwhelm compar chemotherapi combin gemcitabin cisplatin
commonli known target agent evalu clinic trial includ egfr inhibitor inhibitor vascular endotheli growth
factor vegf inhibitor inhibitor fgfr inhibitor idh inhibitor mek inhibitor target agent
evalu single-ag combin chemotherapi understand gene express profil mutat burden
biliari tract cancer could facilit development new therapeut target
approv true standard regimen approv us gemcitabin plu cisplatin regimen wide accept line
therapi base studi howev folfirinox use potenti induct front-lin therapi robust patient
follow gemcitabin backbon therapi line therapi overal gemcitabin backbon therapi follow folfirinox
oxaliplatin vice versa current use treatment option line therapi advanc biliari tract cancer
promis clinic profil kol would want see extend benefit front-lin set doubl
respons rate vs current standard care line set key efficaci measur new agent
median time progress around month line patient durat drop around month line
 current standard care kol estim around respons rate frontlin patient around respons
rate line patient
 target agent promis clinic profil line set kol expect agent doubl respons
rate maintain qualiti life patient accept toler profil agent doubl respons rate
line set manag toler profil even similar current standard care
prescrib note
 howev frontlin set key factor agent need show clear benefit
kol encourag see over-express msi-high statu cholangiocarcinoma could make
immunotherapi viabl option either line line set patient cant toler high dose system
chemotherapi whether high express cholangiocarcinoma translat improv respons rate diseas
control overal surviv remain outstand question cholangiocarcinoma immunolog cold tumor role
immunotherapi indic still unclear someth look forward better understand
incid cholangiocarcinoma
agenttarget intrahepat phase prev treat phase line w/ capecitabin pivot phase ii line w/ capecitabinepivot phase ii line w/ gemcitabin cisplatin phase iicellact pharmacholangiocarcinomaphas iinacellact synthesi endosomepcicholangiocarcinomaphas ramucirumabmet w/ gemcitabin cisplatin phase oxygenepicentrxcholangiocarcinoma line phase line w/ gemcitabin cisplatin phase w/ atezolizumab phase iito w/ gemcitabin cisplatin phase synthesisncnacholangiocarcinoma w/ cisplatin phase synthesisinnopharmax inc cholangiocarcinoma phase tumor phase phase inananalenvatinibvegfreisaicholangiocarcinoma post- gemcitabin phase advanc refractori phase agcholangiocarcinoma phase inayakult honshanaselumetinibmetazn/arrycholangiocarcinoma phase medipharmacholangiocarcinoma line phase iirecruitinghutchison oxaliplatindnastason lxrxcholangiocarcinomapreclinicalnananasourc leerink partner research biomedtrack comstatu clinic preclin candid biliari tract cancer aslan ltd
phase studi establish cisplatin plu
gemcitabin combin refer
chemotherapi regimen advanc biliari tract cancer
median overal surviv month trial
initi design random phase ii
studi later extend phase
base benefit seen progression-fre surviv
 patient local advanc metastat
cholangiocarcinoma gallbladd cancer ampullari
cancer randomli assign receiv cisplatin
plu gemcitabin vs gemcitabin alon
 primari end point overal surviv
 median overal surviv os month cisplatin
gemcitabin arm vs month gemcitabin arm
 median progression-fre surviv month
cisplatingemcitabin arm vs month gemcitabin
phase studi hazard ratio overal surviv
gemcitabin plu cisplatin efficaci biliari tract cancer
annal oncolog
annal oncolog
molecular mutat incid biliari tract cancer ross et al jco
 believ express intrahepat cholangiocarcinoma extrahepat cholangiocarcinoma
phase studi evalu erlotinib plu gemcitabin oxaliplatin newli diagnos metastat biliari tract cancer show
median month combin arm vs month chemotherapy-alon arm
overal surviv howev similar month arm
phase ii studi evalu erlotinib show os overal surviv month median progression-fre surviv
phase ii studi use cetuximab combin gemcitabin oxaliplatin gemox show median progression-fre
surviv month overal surviv month
 express report approxim gallbladd cancer extrahepat cholangiocarcinoma
phase ii studi achiev respons enrol patient patient stabl diseas
progress free surviv month
phase ii studi report median progression-fre surviv month overal surviv os month
line metastat diseas everolimu median progression-fre surviv month
combin bevacizumab plu gemcitabin oxaliplatin gemox-b evalu among patient advanc
median progression-fre surviv month
small line studi evalu combin gemcitabin capecitabin bevacizumab median progression-fre
surviv month overal surviv os month
 antiangiogen agent includ sorafenib sunitinib report respons rate given either
monotherapi combin therapi
nvss phase ii studi advanc cholangiocarcinoma
inci phase ii studi advanc cholangiocarcinoma
arql phase ii studi intrahepat cholangiocarcinoma
phase ii studi selumetinib advanc biliari tract cancer median progression-fre surviv month
overal surviv os month respons rate
phase ii studi show cediranib vegf inhibitor plu gemcitabin cisplatin improv progression-
free surviv gemcitabin cisplatin line patient advanc biliari tract cancer patient
randomli assign line cisplatin gemcitabin chemotherapi either cediranib placebo day diseas
progress primari endpoint progression-fre surviv intention-to-treat popul enrol patient
includ cholangiocarcinoma gallbladd ampulla patient
 median progression-fre surviv month cediranib plu gemcitabin cisplatin arm vs month control
arm gemcitabin cisplatin hr
 respons rate cr pr achiev cediranib arm vs pr control arm
phase open label random studi evalu treatment chemotherapi alon gemcitabin oxaliplatin
chemotherapi plu erlotinib patient metastat biliary-tract cancer primari endpoint progression-fre surviv
signific differ progression-fre surviv note group median progression-fre surviv month
chemotherapi alon group month chemotherapi plu erlotinib group hazard ratio hr
gastric cancer report third lead caus death cancer world-wide around us peopl estim
diagnos gastric cancer peopl eventu die incid gastric cancer howev declin global
incid gastric cancer much higher china countri surviv patient advanc gastric cancer estim
median overal surviv month
 amplif overexpress gastric cancer patient rang respect
 egfr overexpress report advanc gastric cancer patient fuse et al
prognosi patient gastric cancer relat tumor extent includ nodal involv direct tumor extens
beyond gastric wall local distal gastric cancer patient cure howev early-stag diseas account
 case diagnos unit state
 cancer genom atla group identifi four major molecular subtyp frequent around tumor character
chromosom instabl cin amplif gene mainli encod tyrosin kinas receptor ii tumor microsatellit instabl
present high mutat rate dna methyl iii genom stabl tumor iv epstein barr viru posit tumor
character dna hypermethyl high frequenc mutat overexpress
classif report prognost valu surviv differ found among four subgroup
 asian cancer research group identifi group mss microsatellit stabl tumor subdivid basi evid
epitheli mesenchym transit emt presenc wild type inactiv
mss/emt character worst prognosi higher chanc recurr subtyp show best prognosi
advanc metastat set chemotherapi provid improv surviv compar best support care chemotherapi
regimen includ older agent etoposid epirubicin mitomycin fluorouracil cisplatin well new agent irinotecan paclitaxel docetaxel
pegyl doxorubicin capecitabine-bas regimen also evalu sever studi advanc gastric cancer patient
approv target agent advanc metastat gastric cancer includ trastuzumab ramucirumab pembrolizumab
tumor sever agent target egfr immun checkpoint shown encourag result advanc metastat gastric cancer
patient number approv agent limit biolog heterogen gastric cancer could partial explain limit success seen
target therapi
 toga studi establish herceptin combin chemotherapi new standard care patient advanc
metastat gastric cancer howev benefit limit patient tumor score fish posit
surviv benefit patient fish posit
incid gastric cancer age-adjust incid per
gastric cancer molecular classif propos cancer genom atla asian cancer
classif report
prognost valu surviv differ
found among four subgroup
mss/emt character worst prognosi
higher chanc recurr
subtyp show best prognosi
agenttarget moatickerindicationstagestatussponsoridentifiercyramzavegfrllygastr cancer metastat post fluoropyrimidin pt tx approvedapprovedgastr cancer metastat line w/ paclitaxel ph cancer metastat line w/ capecitabin plu cisplatin ph cancer metastat line w/ bsc ph cancer metastat cancer advanc w/ chemo ph cancer metastat w/ cisplatin capecitabin ph heloisetermin cancer metastat line later approv acceler approv acceler gastric cancer metastat line ph cancer metastat line w/ /- cisplatin cancer neoadjuvant/adjuv w/ chemo ph cancer advanc line w/ folfox ph cancer recurr w/ nivolumab ph cancer advanc line mainten ph javelin gastric cancer recurr line ph javelin gastric synthesistaihogastr cancer metastat w/ bsc ph cancer advanc line w/ ipilimumab ph biopartnersgastr cancer metastat w/ bsc ph angelrecruitinglsk cancer advanc line ph nananavarlitinibpan-heraslangastr cancer line w/ folfox ph cancer metastat amplifi ph cancer advanc cancer line ph nananaonivydetopo-iipsengastr cancer line ph cancer w/ io agent ph cancer metastat w/ tremelimumab ph cancer r/r w/ pembrolizumab ph cancer w/ combo agent ph cancer w/ fightto cancer line w/ paclitaxel ph recruitinghutchison cancer advanc ph caner line ph ii list includ select trial given agenth target agentssourc leerink partner research biomedtrack comkey select clinic candid gastric cancer aslan ltd
co-express egfr c-met
fuse et al investig co-overexpress egfr c-met
advanc gastric cancer patient receiv standard chemotherapi
 patient nine institut patient posit
patient egfr posit patient c-met
 patient show posit co-express egfr c-met
median follow-up time month death
signific differ overal surviv os term egfr statu
howev signific differ os c-met-posit c-
os curv stratifi egfr c-met fuse et al
os curv gastric cancer patient variou express
reduc os amplifi gastric cancer
reduc os posit gastric cancer
overexpress significantli associ
poor prognosi howev regard
treatment target view inact tyrosin kinas domain
fail show os
fail show os
fail show os
fail show
fail show os
toga trastuzumab gastric cancer phase open-label random control trial enrol patient
gastric gastro-esophag junction cancer patient randomli assign ratio
receiv either chemotherapi regimen consist capecitabin plu cisplatin herceptin combin fluorouracil plu
cisplatin primari endpoint overal surviv os random patient
 median overal surviv os month assign trastuzumab plu chemotherapi compar month
assign chemotherapi alon hazard ratio
toga studi respons rate secondari point
toga studi exploratori analysi base statu
toga studi os curv fish
base efficaci metastat breast cancer phase jacob trial evalu combin perjeta
pertuzumab herceptin trastuzumab plu chemotherapi vs herceptin plu chemotherapi alon jacob trial
patient random receiv herceptin/chemotherapi standard cisplatin/fluoropyrimidin regimen without perjeta
therapi continu diseas progress primari endpoint overal surviv os
 jacob estim power detect signific improv overal surviv hazard ratio hr
final efficaci analysi event
 median follow-up approxim year median overal surviv os month perjeta plu herceptin arm
vs month herceptin arm hr although increas surviv achiev studi narrowli
fail meet primari endpoint
jacob studi os result
european societi medic oncolog esmo biomedtrack
gsk announc phase logic studi tykerb lapatinib combin chemotherapi previous
untreat patient advanc gastric cancer meet primari endpoint improv overal surviv
os vs chemotherapi alon double-blind random phase studi random patient
capeox capecitabin oxaliplatin plu tykerb mg lapatinib arm capeox plu placebo
placebo arm prior palli chemotherapi allow prior treatment oxaliplatin-bas neoadjuv adjuv
chemotherapi could complet month studi entri
 median os tykerb placebo arm month respect significantli differ hr
 median tykerb placebo arm month respect
 respons rate significantli higher tykerb arm vs placebo arm
logic studi os curv efficaci popul
logic studi curv efficaci popul
octob roch disclos gatsbi trial assess kadcyla ado-trastuzumab emtansin
treatment advanc gastric cancer meet primari endpoint gatsbi phase ii/iii random
open-label studi enrol advanc gastric cancer patient progress therapi
primari endpoint overal surviv os intention-to-treat popul median overal surviv month
trastuzumab emtansin month taxan treatment hr one-sid
gatsbi studi respons rate popul
phase expand studi random open-label trial enrol unselect advanc gastric cancer
patient either chemotherapi arm capecitabin plu cisplatin chemotherapi plu cetuximab arm primari endpoint
progression-fre surviv overal addit cetuximab capecitabin cisplatin unselect patient
advanc gastric gastro-esophag junction cancer provid benefit compar chemotherapi alon find
gener consist subgroup
 median capecitabine-cisplatin plu cetuximab arm month vs month capecitabine-cisplatin alon
phase studi open-label trial enrol patient untreat metastat local advanc gastric
cancer evalu panitumumab combin chemotherapi elig patient randomli alloc receiv
either eoc epirubicin oxaliplatin capecitabin eoc plu panitumumab primari endpoint overal surviv
intention-to-treat popul addit panitumumab eoc chemotherapi increas overal surviv os
 median overal surviv os month eoc chemotherapi arm vs month panitumumab plu eoc chemotherapi
phase ii open-label single-arm studi enrol later line metastat gastric cancer patient
receiv keytruda monotherapi keytruda monotherapi demonstr singl agent activ manag safeti patient
indic approv acceler approv base tumor respons rate durabl respons
 primari end point object respons rate safeti object respons rate assess central radiolog review per
respons evalu criteria solid tumor version patient tumor
 overal object respons rate complet respons patient median respons durat month
 patient object respons rate median respons durat month
 patient object respons rate median respons durat month
rate base express
oral inhibitor dhodh potenti first-in-class aml compani licens
almiral almiral complet phase singl ascend dose studi aslan current conduct phase ii clinic trial
asia evalu drug aml compani also explor solid tumor type tripl neg breast cancer tnbc
hepatocellular carcinoma dhodh inhibit could relev
inhibit dhodh believ deplet intracellular pool pyrimidin contribut lower level atp
adenosin triphosph increas level adenosin triphosph atp pyrimidin requir tumor growth
surviv report two order magnitud potent inhibit dhodh first gener dhodh
inhibitor leflunomid teriflunomid aslan shown half-lif hour could allow daili dose per aslan
manag also shown higher potenc teriflunomid vitro assay accord manag exposur
could result approxim inhibit dhodh taken daili comparison maximum dose
teriflunomid lead inhibit
could potenti favor pharmacokinet profil vs first gener dhodh inhibitor first gener
dhodh inhibitor leflunomid teriflunomid believ take three four week build therapeut level
two year clear complet dose stop per aslan manag contrast report reach full
exposur hour half-lif hour allow rapid clearanc follow cessat treatment moreov leflunomid
teriflunomid associ signific liver toxic
on-going phase ii trial relaps refractori aml interim data expect aslan initi
phase ii clinic trial relapsed/refractori aml singapor australia compani intend initi recruit
patient trial test three dose aml popul monotherapi day progress
 primari endpoint rate complet remiss cr complet remiss incomplet bone marrow recoveri
thereaft expans cohort expect enrol addit patient potenti combin standard
 previous phase singl multipl ascend dose studi demonstr dose proport pharmacokinet
accumul healthi subject dose healthi subject report well-toler
singl ascend multipl ascend dose maximum dose daili
phase ii studi relaps refractori aml
safeti profil multipl ascend dose mad
bayer current phase studi myeloid malign phase studi start march
estim enrol compris dose-escal portion acut myeloid leukemia aml myelodysplast syndrom
md chronic myelomonocyt leukemia cmml two expans cohort one aml one md
potent select bioavail dhodh inhibitor block ubiquinon bind site dhodh
demonstr preclin broad specif anti-prolif activ across multipl cell line also
demonstr anti-tumor efficaci aml xenograft model increas plasma dho level indic target engag
also demonstr reduct tumor burden increas surviv aml xenograft pdx model vivo
agio dhodh inhibitor ind
submiss april enter
global licens agreement aurigen discoveri
technolog limit research develop
commerci small molecul inhibitor dhodh
receiv exclus right aurigen portfolio
small molecul dhodh aurigen receiv
up-front payment potenti mileston
aurigen also elig receiv low single-
digit royalti net product sale
fulli human monoclon antibodi target receptor subunit
inhibit signal central trigger symptom allergi
atop dermat red itch skin well asthma symptom short breath
wheez cough
aslan licens world-wide right previous may
develop plan timelin
current preclin develop
aslan expect file ind applic aslan conduct phase clinic trial asthma
 manag look out-licens oncolog indic
similar target pathway regeneron op approv dupix dupilumab
 dupilumab receptor alpha antagonist human monoclon antibodi subclass bind il-
subunit inhibit signal dupilumab market sever atop dermat recent complet
success phase clinic trial asthma
 target pathway dupilumab asln believ narrow cellular distribut
receptor could offer lower dose lower dose frequenc import featur
subcutan inject provid greater patient conveni addit select bind dupilumab
could give favor side effect profil dupilumab
small molecul dual inhibitor ron cmet receptor tyrosin kinas
phase studi show well toler phase data also demonstr
inhibit ron result suppress plasma c-termin telopeptid level establish biomark
osteoclast activ therefor ron inhibit
bristol-my squibb nyse reacquir right bm respons
develop commerci activ
timelin develop
longer list bristol-my squibb pipelin develop solid tumor
timelin develop plan unclear origin slate develop solid tumor possibl focus
gastric cancer
august bristol-my squibb reacquir right bm china australia korea
taiwan asian territori
 aslan in-licens above-ment market bristol-my squibb novemb
aslan receiv up-front payment million elig receiv develop regulatori
mileston excess million
addit aslan elig receiv royalti payment futur world-wide sale
bristol-my squibb resum respons develop commerci activ expens
evalu safeti determin
patient advanc metastat solid tumor
oral twice daili
dose escal cohort daili
patient includ across dose cohort cohort mg bid open due lack appreci
pharmacokinet pk differ mg bid mg bid higher incid grade advers event ae
fifteen patient experienc grade ae commonli report nausea fatigu
constip one dose limit toxic dlt atrial fibril observ mg bid
twice daili recommend phase ii dose
pk studi critic determin proport increas drug exposur dose
despit activ kinas relat similar toxic seen
 toxic inhibitor like relat off-target kinas inhibit grade hypertens cabozantinib
palmar-plantar erythema cabozantinib hypophosphatemia foretinib increas lipas foretinib rise transaminas
diseas control rate seen compar non-select inhibitor patient
stabl diseas patient progress diseas remain patient respons evalu
c-met receptor origin nant ron
c-met ron express mani cancer type
lead aberr signal contribut cancer
develop progress
 express associ wors clinic prognosi
aggress differ tumor type
although often co-express distinct function role
c-met ron fulli understood c-met
ron form activ homodim heterodim
famili phosphotyrosin
ligand bind hgf c-met macrophag
stimul protein msp ron result dimer
phosphoryl conform chang thu
paper preclin data show ron inhibit reduc metastat outgrowth
treatment ron inhibitor significantli reduc metastat
outgrowth quantif metastat tumor burden lung
mice treat prophylact vehicl versu mg/kg bms-
 percentag lung area occupi
metastat growth lung mice treat vehicl
paper ron inhibit show potenti treat bone destruct diseas
knockout ron alon cancer cell line found prevent
instead ron inhibition/knockout shown block bone osteolysi
cmet kinas inhibit necessari reduc tumor burden
could affect bone turnov human subject treat drug
context phase clinic trial cancer patient
plasma sampl phase patient examin evid bone turnov baselin
treatment use clinic test detect cleav bone-deriv
collagen plasma bcross-link c-telopeptid
correl data consid togeth preclin data anim model
vitro indic inhibit ron reduc osteoclast activ result provid rational
continu investig use ron inhibitor treat bone destruct diseas
osteolyt bone metastasi osteoporosi
inhibitor c-met ron includ small molecular weight kinas inhibitor neutral antibodi
pre-clin investig clinic trial sever tyrosin kinas inhibitor activ c-met
ron kinas wherea antibodi gener target specif
awar anti-ron-specif program current suspend
 narnatumab anti-ron-mab
narnatumab recent suspend phase trial solid tumor phase show narnatumab well toler
show limit antitumor activ dose regimen
 aveo pharmaceut inc johnson johnson partner develop anti-ron mab partnership
termin undisclos reason
signific evid express amplif upregul ligand hepatocyt growth factor hgf contribut cancer
metastasi effect surviv simpli much intens studi target much less data ron
fda approv multipl
aslan licens royalti p/w- product sale p/w- total sg total oper oper incom total incom expens incom tax- net incom common share outstand common share outstand ep epad sourc sec file leerink partner estimatesaslan bs cf sourc sec file leerink partner estim aslan ltd
varlitinib sale biliari tract cancer line us varlitinib biliari tract cancer line china varlitinib gastric cancer- total sales- royalti biliari tract cancer row varlitinib gastric cancer- total royalties- product revenu p/w biliari tract cancer line varlitinib biliari tract cancer line varlitinib gastric total sales- royalti p/w biliari tract cancer line varlitinib gastric total royalties- sourc leerink partner estim aslan ltd
 varlitinib licens arri
famili composition-of-matt patent normal expir novemb us
pend patent mostli relat medic use combin therapi normal expir grant
 licens almiral
composit matter famili patent normal expir famili patent decemb
 licens
composit matter famili patent normal expir famili patent octob
 aslan out-licens arrang bristol-my squibb hyundai
 hyundai varlitinib
januari aslan enter new licens agreement array aslan obtain exclus
world-wide licens develop manufactur commerci varlitinib human anim therapeut diagnost
octob aslan enter collabor licens agreement hyundai hyundai receiv
right develop option commerci varlitinib treatment cholangiocarcinoma south korea aslan
receiv up-front payment hyundai hyundai also retain option obtain develop
commerci right varlitinib treatment gastric cancer breast cancer south korea
 bm
novemb aslan enter licens agreement bristol-my aslan receiv exclus
right develop commerci china australia south korea taiwan select asian countri
bristol retain exclus right rest world
juli bristol initi right buy back exclus right aslan develop commerci
aslan receiv up-front payment also elig receiv addit mileston payment aslan
also elig receiv royalti payment futur world-wide sale
descript kol practic
 patient predominantli hepato-pancreato-biliari hpb patient malign
 approxim gastric esophag remain liver pancrea bile duct cancer patient order
 overal subtyp cholangiocarcinoma cca probabl treat patient cca per month subtyp
 treat gastric-esophag junction gastric adenocarcinoma month
 three differ group present differ type underli biolog prognost challeng
first group intrahepat
patient present present multifoc type diseas liver diseas usual bilobar
numer satellit lesion usual mani count domin cm tumor bilobar diseas
second group perihilar extrahepat
perihilar diseas typic present either extens lymph node metastas abdomen periton diseas
challeng perihilar high hematogen spread occur along high rate recurr hematogen
biggest challeng defin patient truli resect unresect time diagnosi dont current good
imag modal allow us assess delin abil resect high rate resect
addit without good imag dont know get neoadjuv chemo prior resect kol opinion everyon
third group distal extrahepat
distal patient commonli slightli favor prognosi
typic treat abraxan folfirinox surgic resect
 upper gi cancer pancreat adenocarcinoma worst bile duct ampullari duoden
 one averag patient stage median os stage cca approxim month admittedli larg
rang depend diseas identifi earli
genet biomark prognost factor
cca patient molecularli genotyp
look target agent vegf nra kra braf assess prognost indic mayb open patient angiogen
inhibitor base studi
encourag slightli higher overexpress msi-high
usual though keep immunotherapi avail either line therapi patient cant toler high dose system
despit enthusiasm molecular marker test get insur compani pay non-tradit treatment cca
standard line
 true standard approv regimen us
 peopl embrac trial even though year old
subset medic oncologist use gemcitabin plu cisplatin
 slight movement especi younger robust patient use folfirinox
allow gemcitabine/cisplatin save line therapi
 part chemotherapeut option cca mirror pancreat adenocarcinoma option
 patient failed/becom intoler option look start target agent immunotherapi clinic trial
respons rate line
 recurr rate patient ultim diseas recurr fail treatment
 line month across patient line bit lower month
 line respons rate least reduct diseas occur patient diseas control usual occur patient
line
 line respons rate diseas control rate
cca studi complet on-going
 trial establish gemcitabin plu cisplatin option one first posit trial ever
 peopl intrigu immunotherapi trial use opdivo interest express cca way higher
pancreat adenocarcinoma question whether translat improv rr diseas control os peopl question
potenti trial histor cca view immunolog cold
rational target famili receptor
 cca valid without doubt
 even biopsi tumor come back posit get patient herceptin plu gemcitabin plu cisplatin would
difficult current investig compassion use state
 say dont believ target could help say cant get therapi paid for/cov insur use
salvag treatment instanc effect
 data look intrigu combin strategi make sens
 would plead tri fast track line even adjuv therapi seem similar side effect profil sorafenib
problem use side effect
 varlitinib studi seem accept side effect profil
respons rate would consid good line
 drug need doubl respons rate diseas control rate
get rr rang
 realiti rr need doubl drug expens without doubl rr nobodi use exampl regorafenib
line
 even remain varlitinib could doubl rr would prescrib side effect toler
median month interest make month miser side effect
respons rate rr progress free surviv would consid good line
 rr need push high even
 howev line drug push line peopl motiv rr motiv truli
prolong patient diseas state prevent progress
 peopl still use dcf docetaxel cisplatin ecf epirubicin cisplatin
 mani peopl switch oxaliplatin backbon therapi similar rr dcr metastat diseas
 landscap choic chemo surgeri depend statu follow fit patient
desir aggress line use dcf ecf keep oxaliplatin open line
patient frail/much extens diseas comorbid like use folfox therapi toler better
mani trial fail gastric cancer
 main reason poor imag
compani spend ton ae evalu wont allow effect imag dont central imag dont review
imag much imag come pet scan poor qualiti ct scan
 addit diseas distribut burden enrol trial extrem variabl caus variabl result
 kol opinion compani believ therapi work everybodi fact least differ degre local
advanc gastric cancer behav differ
believ need captur creat initi adapt trial design modifi power inclus criteria
compani includ posit that get burn
target egfr valid approach gastric cancer varlitinib egfr coexpressor
 definit valid test dont sens incid coexpress
 know signific racial demograph differ asia us eu gastric target express
 understand incid coexpress import coexpress low ex may worth
rate coexpress
 coexpress sound way high us express alon gastric nowher near therefor look coexpress
there way high
 best guess us coexpress would gener less coexpress would optimist guess
 south korea japan howev believ coexpress
cetuximab fail improv os would agent target egfr work
 tri extrapol neg studi weve seen cetuximab doesnt alway correl may requir addit type
stimul requir anoth type method action weve seen cetuximab folfirinox activ
two hit phenomenon
 lot multi target therapi critic dont egocentr think theyll get great monotherapi activ wont
realiti like need kind backbon whether system chemo backbon whether surgic backbon whether
radiat backbon think youv got keep
agent clinic develop get excit
 excit strong word sure im excit still see earli stage develop small phase
larger phase ii therapi develop monotherapi random combin chemo backbon versu
 want see drug move line mani drug start develop line latest latest patient
thing excit
 know current line good move evalu clinic relev stage would thing could get
aslan mm
collabor licens revenu
total incom expens net
sec file leerink partner estim
aslan bs cf mm
sec file leerink partner estim
aslan pipelin upcom event
ph i/ii line ist
compani file leerink partner estim
aslan dcf analysi mm
